Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, CRISPR THERAPEUTICS AG reported revenue of $4M, down 90.6% year over year. Operating margin was -18933.6% and net margin -16569.8%, on a free-cash-flow margin of -9855.5% with capital expenditure at 26.0% of revenue. Every figure is computed directly from CRSP's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $4M | -18933.6% | -16569.8% |
| FY2024 | $37M | -1250.4% | -981.5% |
| FY2023 | $371M | -60.0% | -41.4% |
| FY2022 | $1M | -56190.4% | -54271.7% |
| FY2021 | $915M | 40.8% | 41.3% |
How does CRSP compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.